Ex Vivo Transposon-Mediated Genetic Screens for Cancer Gene Discovery

2Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Transposon mutagenesis has emerged as a powerful methodology for functionally annotating cancer genomes. Although in vivo transposon-mediated forward genetic screens have proven to be valuable for cancer gene identification, they are also time consuming and resource intensive. To facilitate the rapid and cost-effective identification of genes that regulate tumor-promoting pathways, we developed a complementary ex vivo transposon mutagenesis approach wherein human or mouse cells growing in culture are mutagenized and screened for the acquisition of specific phenotypes in vitro or in vivo, such as growth factor independence or tumor-forming ability. This approach allows discovery of both gain- and loss-of-function mutations in the same screen. Transposon insertions sites are recovered by high-throughput sequencing. We recently applied this system to comprehensively identify and validate genes that promote growth factor independence and transformation of murine Ba/F3 cells. Here we describe a method for performing ex vivo Sleeping Beauty-mediated mutagenesis screens in these cells, which may be adapted for the acquisition of many different phenotypes in distinct cell types.

Cite

CITATION STYLE

APA

O’Donnell, K. A., Guo, Y., Suresh, S., Updegraff, B. L., & Zhou, X. (2019). Ex Vivo Transposon-Mediated Genetic Screens for Cancer Gene Discovery. In Methods in Molecular Biology (Vol. 1907, pp. 145–157). Humana Press Inc. https://doi.org/10.1007/978-1-4939-8967-6_12

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free